Compare YDKG & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YDKG | SILO |
|---|---|---|
| Founded | 2005 | 2010 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Apparel |
| Sector | Consumer Discretionary | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9M | 4.5M |
| IPO Year | N/A | N/A |
| Metric | YDKG | SILO |
|---|---|---|
| Price | $1.04 | $0.38 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 140.0K | ★ 168.2K |
| Earning Date | 03-06-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,107,000.00 | $72,102.00 |
| Revenue This Year | N/A | $1.86 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2175.52 | N/A |
| 52 Week Low | $0.81 | $0.33 |
| 52 Week High | $669.00 | $2.09 |
| Indicator | YDKG | SILO |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 45.06 |
| Support Level | N/A | $0.37 |
| Resistance Level | N/A | $0.40 |
| Average True Range (ATR) | 0.00 | 0.02 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 0.00 | 55.44 |
Yueda Digital Holding is a digital-economy company with a focus on the long-term accumulation of mainstream cryptocurrencies. The business activities of the company include active treasury management of mainstream digital assets, exploration of compliant, risk-managed yield opportunities, such as staking, on-chain liquidity provision, and other conservative market activities, selective investments and partnerships in Web3 infrastructure and applications, and advisory services for enterprises entering the digital-asset economy.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.